ImmunoMolecular Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes
Phase 1
Completed
- Conditions
- Type1 Diabetes
- Interventions
- Drug: 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsuleDrug: 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsuleDrug: 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsuleDrug: 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Immunomolecular Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04625595
- Locations
- 🇺🇸
Barbara Davis Center, Aurora, Colorado, United States
🇺🇸Prosciento, Inc., Chula Vista, California, United States
🇺🇸Rainier Clinical Research Center, Renton, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath